ERBB2 and neoplasm: A substantial body of evidence from clinical studies has demonstrated that compared to patients without DTCs, those with DTC positivity have features of aggressive tumor biology, including larger tumor size, higher grade, axillary lymph node metastasis, estrogen/progesterone receptor negativity, and HER2 positivity [182,183].